Disease:
Stroke

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available No VIP available VA CYP2C19 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *3 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *4 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *8 N/A N/A N/A
No VIP available No VIP available VA CYP2C19 *17 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *1 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *2 N/A N/A N/A
No VIP available No VIP available VA CYP2C9 *3 N/A N/A N/A
No VIP available No Clinical Annotations available VA
rs1045642 NC_000007.13:g.87138645A>G, NC_000007.14:g.87509329A>G, NG_011513.1:g.208920T>C, NM_000927.4:c.3435T>C, NP_000918.2:p.Ile1145=, rs10239679, rs11568726, rs117328163, rs17210003, rs2229108, rs386513066, rs60023214, rs9690664
A > G
SNP
I1145I
No VIP available No Clinical Annotations available VA
rs1062535 NC_000005.10:g.53055583G>A, NC_000005.9:g.52351413G>A, NG_008330.1:g.71258G>A, NM_002203.3:c.825G>A, NP_002194.2:p.Thr275=, NR_073103.1:n.968G>A, NR_073104.1:n.968G>A, NR_073105.1:n.968G>A, NR_073106.1:n.968G>A, NR_073107.1:n.847G>A, rs3733877
G > -
G > A
SNP
T275T
No VIP available No Clinical Annotations available VA
rs10935842
T > A
SNP
No VIP available No Clinical Annotations available VA
rs11039149 NC_000011.10:g.47255124A>G, NC_000011.9:g.47276675A>G, NG_030392.1:g.11825A>G, NM_001130102.2:c.-92-4667A>G, NM_001251934.1:c.62-4667A>G, NM_001251935.1:c.62-4667A>G, XM_005252713.1:c.-37-4056A>G, XM_005252713.2:c.-37-4056A>G, XM_005252716.1:c.-92-4667A>G, XM_005252716.2:c.-92-4667A>G, XM_005252717.1:c.-97-4662A>G, XM_005252718.1:c.-92-4667A>G, XM_005252718.2:c.-92-4667A>G, XM_011519805.1:c.-37-4056A>G, XM_011519808.1:c.-137-6117A>G, rs60920446
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1126643 NC_000005.10:g.53051539C>T, NC_000005.9:g.52347369C>T, NG_008330.1:g.67214C>T, NM_002203.3:c.759C>T, NP_002194.2:p.Phe253=, NR_073103.1:n.902C>T, NR_073104.1:n.902C>T, NR_073105.1:n.902C>T, NR_073106.1:n.902C>T, NR_073107.1:n.781C>T, rs11549773, rs16880736, rs1800198
C > -
C > T
SNP
F253F
No VIP available No Clinical Annotations available VA
rs12041331 NC_000001.10:g.156869714G>A, NC_000001.11:g.156899922G>A, NM_001080471.1:c.-9-3996G>A, XM_005245141.1:c.-168-2266G>A, XM_005245141.2:c.-168-2266G>A, XM_006711302.2:c.-168-2266G>A, XM_011509508.1:c.-164-2266G>A, XM_011509509.1:c.-107-2266G>A, XM_011509510.1:c.-107-2266G>A, XM_011509511.1:c.-168-2266G>A, XM_011509512.1:c.-494-3996G>A, rs56433638, rs60733787
G > A
SNP
No VIP available No Clinical Annotations available VA
rs12143842 NC_000001.10:g.162033890C>T, NC_000001.11:g.162064100C>T, rs59411707
C > T
SNP
No VIP available No Clinical Annotations available VA
rs12221497 NC_000011.10:g.47259102G>A, NC_000011.9:g.47280653G>A, NG_030392.1:g.15803G>A, NM_001130101.2:c.-37-78G>A, NM_001130102.2:c.-92-689G>A, NM_001251934.1:c.62-689G>A, NM_001251935.1:c.62-689G>A, NM_005693.3:c.-37-78G>A, XM_005252704.1:c.95-689G>A, XM_005252705.1:c.-37-78G>A, XM_005252706.1:c.-37-78G>A, XM_005252707.1:c.-115G>A, XM_005252707.3:c.-115G>A, XM_005252708.1:c.95-689G>A, XM_005252709.1:c.-177-78G>A, XM_005252710.1:c.-177-78G>A, XM_005252711.1:c.-597G>A, XM_005252712.1:c.-37-78G>A, XM_005252713.1:c.-37-78G>A, XM_005252713.2:c.-37-78G>A, XM_005252714.1:c.95-689G>A, XM_005252715.1:c.-37-78G>A, XM_005252715.2:c.-37-78G>A, XM_005252716.1:c.-92-689G>A, XM_005252716.2:c.-92-689G>A, XM_005252717.1:c.-97-684G>A, XM_005252718.1:c.-92-689G>A, XM_005252718.2:c.-92-689G>A, XM_006718112.1:c.-37-78G>A, XM_006718113.1:c.-37-78G>A, XM_006718114.2:c.-115G>A, XM_006718115.1:c.-177-78G>A, XM_006718116.1:c.-92-689G>A, XM_011519805.1:c.-37-78G>A, XM_011519806.1:c.-92-689G>A, XM_011519807.1:c.-92-689G>A, XM_011519808.1:c.-137-2139G>A, rs59819109
G > A
SNP
No VIP available No Clinical Annotations available VA
rs12487835
C > T
SNP
No VIP available No Clinical Annotations available VA
rs12497330
G > A
SNP
No VIP available No Clinical Annotations available VA
rs12637988
T > A
SNP
No VIP available No Clinical Annotations available VA
rs1491974
A > G
SNP
No VIP available No Clinical Annotations available VA
rs16863336
C > T
SNP
No VIP available No Clinical Annotations available VA
rs16863356
G > A
SNP
No VIP available No Clinical Annotations available VA
rs17110453 NC_000010.10:g.96829529A>C, NC_000010.11:g.95069772A>C, NG_007972.1:g.4726T>G, NM_000770.3:c.-370T>G, NM_001198853.1:c.-618T>G, NM_001198854.1:c.-551T>G, NM_001198855.1:c.-680T>G, XR_246073.1:n.-274T>G, XR_945610.1:n.-274T>G, rs386542449, rs56470669, rs57410615
A > C
SNP
No VIP available CA VA
rs1799963 NC_000011.10:g.46739505G>A, NC_000011.9:g.46761055G>A, NG_008953.1:g.25313G>A, NM_000506.4:c.*97G>A, NM_001311257.1:c.*97G>A, XR_428840.2:n.1828G>A
G > A
SNP
No VIP available No Clinical Annotations available VA
rs1799983 NC_000007.13:g.150696111T>G, NC_000007.14:g.150999023T>G, NG_011992.1:g.12965T>G, NM_000603.4:c.894T>G, NM_001160109.1:c.894T>G, NM_001160110.1:c.894T>G, NM_001160111.1:c.894T>G, NP_000594.2:p.Asp298Glu, NP_001153581.1:p.Asp298Glu, NP_001153582.1:p.Asp298Glu, NP_001153583.1:p.Asp298Glu, XM_006716002.2:c.894T>G, XP_006716065.1:p.Asp298Glu, rs11266811, rs13238975, rs13305983, rs13308813, rs17173672, rs3730304, rs57135373
T > G
SNP
D298E
No VIP available CA VA
rs1801020 NC_000005.10:g.177409531A>G, NC_000005.9:g.176836532A>G, NG_007568.1:g.5046T>C, NM_000505.3:c.-4T>C, XM_011534461.1:c.-4T>C, rs17876008, rs3749733, rs386545613
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1907637
A > G
SNP
No VIP available No Clinical Annotations available VA
rs1934980 NC_000010.10:g.96808973A>G, NC_000010.11:g.95049216A>G, NG_007972.1:g.25282T>C, NM_000770.3:c.820-3265T>C, NM_001198853.1:c.610-3265T>C, NM_001198854.1:c.514-3265T>C, NM_001198855.1:c.610-3265T>C, XR_246073.1:n.916-3265T>C, XR_945610.1:n.916-3265T>C, rs11572137, rs17558365, rs4630230, rs59199142
A > G
SNP
No VIP available No Clinical Annotations available VA
rs200148 NC_000006.11:g.143345696G>A, NC_000006.12:g.143024559G>A, NR_038987.1:n.595-2606C>T, rs61230468, rs629392
G > A
SNP
No VIP available No Clinical Annotations available VA
rs20417 NC_000001.10:g.186650321C>G, NC_000001.11:g.186681189C>G, NG_028206.2:g.4239G>C, NM_000963.3:c.-899G>C, NR_125801.1:n.536C>G, rs11567816
C > G
SNP
No VIP available No Clinical Annotations available VA
rs2046934 NC_000003.11:g.151057642G>A, NC_000003.12:g.151339854G>A, NG_016019.1:g.49903C>T, NG_021244.1:g.257967G>A, NM_022788.4:c.-15+742C>T, NM_053002.5:c.2146-10205G>A, NM_176876.2:c.-15+742C>T, XM_005247096.1:c.2251-10205G>A, XM_006713487.2:c.2251-10205G>A, XM_011512386.1:c.2251-10205G>A, XM_011512387.1:c.2251-10205G>A, XM_011512388.1:c.2251-10205G>A, XM_011512389.1:c.2146-10205G>A, XM_011512390.1:c.2146-10205G>A, XM_011512391.1:c.1981-10205G>A, XM_011512392.1:c.1795-10205G>A, XM_011512393.1:c.2251-10205G>A, XM_011512394.1:c.2251-10205G>A, XM_011512395.1:c.2251-10205G>A, XM_011512396.1:c.676-10205G>A, XM_011512398.1:c.46-10205G>A, XM_011512399.1:c.2251-10205G>A, rs59362541
G > A
SNP
No VIP available No Clinical Annotations available VA
rs2242480 NC_000007.13:g.99361466C>T, NC_000007.14:g.99763843C>T, NG_008421.1:g.25343G>A, NM_001202855.2:c.1023+12G>A, NM_017460.5:c.1026+12G>A, XM_011515841.1:c.1026+12G>A, XM_011515842.1:c.1023+12G>A, rs10364667, rs12721630, rs17161804, rs28969389, rs59491337, rs72494459, rs9655766
C > T
SNP
No VIP available No Clinical Annotations available VA
rs2279238 NC_000011.10:g.47260473C>T, NC_000011.9:g.47282024C>T, NG_030392.1:g.17174C>T, NM_001130101.2:c.297C>T, NM_001130102.2:c.162C>T, NM_001251934.1:c.315C>T, NM_001251935.1:c.315C>T, NM_005693.3:c.297C>T, NP_001123573.1:p.Ser99=, NP_001123574.1:p.Ser54=, NP_001238863.1:p.Ser105=, NP_001238864.1:p.Ser105=, NP_005684.2:p.Ser99=, XM_005252704.1:c.348C>T, XM_005252705.1:c.297C>T, XM_005252706.1:c.297C>T, XM_005252707.1:c.297C>T, XM_005252707.3:c.297C>T, XM_005252708.1:c.348C>T, XM_005252709.1:c.162C>T, XM_005252710.1:c.162C>T, XM_005252711.1:c.162C>T, XM_005252712.1:c.297C>T, XM_005252713.1:c.297C>T, XM_005252713.2:c.297C>T, XM_005252714.1:c.283+494C>T, XM_005252715.1:c.232+494C>T, XM_005252715.2:c.232+494C>T, XM_005252716.1:c.97+494C>T, XM_005252716.2:c.97+494C>T, XM_005252717.1:c.162C>T, XM_005252718.1:c.97+494C>T, XM_005252718.2:c.97+494C>T, XM_006718112.1:c.297C>T, XM_006718113.1:c.297C>T, XM_006718114.2:c.297C>T, XM_006718115.1:c.162C>T, XM_006718116.1:c.162C>T, XM_011519805.1:c.297C>T, XM_011519806.1:c.162C>T, XM_011519807.1:c.97+494C>T, XM_011519808.1:c.-137-768C>T, XP_005252761.1:p.Ser116=, XP_005252762.1:p.Ser99=, XP_005252763.1:p.Ser99=, XP_005252764.1:p.Ser99=, XP_005252765.1:p.Ser116=, XP_005252766.1:p.Ser54=, XP_005252767.1:p.Ser54=, XP_005252768.1:p.Ser54=, XP_005252769.1:p.Ser99=, XP_005252770.1:p.Ser99=, XP_005252774.1:p.Ser54=, XP_006718175.1:p.Ser99=, XP_006718176.1:p.Ser99=, XP_006718177.1:p.Ser99=, XP_006718178.1:p.Ser54=, XP_006718179.1:p.Ser54=, XP_011518107.1:p.Ser99=, XP_011518108.1:p.Ser54=
C > T
SNP
S99S
No VIP available CA No Variant Annotations available
rs28371685 NC_000010.10:g.96740981C>T, NC_000010.11:g.94981224C>T, NG_008385.1:g.47567C>T, NM_000771.3:c.1003C>T, NP_000762.2:p.Arg335Trp, XM_005269575.1:c.1003C>T, XP_005269632.1:p.Arg335Trp, rs60219528
C > T
SNP
R335W
No VIP available CA No Variant Annotations available
rs28371686 NC_000010.10:g.96741058C>G, NC_000010.11:g.94981301C>G, NG_008385.1:g.47644C>G, NM_000771.3:c.1080C>G, NP_000762.2:p.Asp360Glu, XM_005269575.1:c.1080C>G, XP_005269632.1:p.Asp360Glu, rs57527516
C > G
SNP
D360E
No VIP available No Clinical Annotations available VA
rs4244285 NC_000010.10:g.96541616G>A, NC_000010.11:g.94781859G>A, NG_008384.2:g.24154G>A, NM_000769.1:c.681G>A, NM_000769.2:c.681G>A, NP_000760.1:p.Pro227=, rs116940633, rs17879456, rs60361278
G > A
SNP
P227P
No VIP available No Clinical Annotations available VA
rs4603933
T > G
SNP
No VIP available No Clinical Annotations available VA
rs4986893 NC_000010.10:g.96540410G>A, NC_000010.11:g.94780653G>A, NG_008384.2:g.22948G>A, NM_000769.2:c.636G>A, NP_000760.1:p.Trp212Ter, rs52827375, rs57081121
G > A
SNP
W212*
No VIP available CA No Variant Annotations available
rs5065 NC_000001.10:g.11906068A>G, NC_000001.11:g.11846011A>G, NG_012926.1:g.6773T>C, NM_006172.3:c.454T>C, NP_006163.1:p.Ter152Arg, NR_037806.1:n.1479+245A>G, rs1130764, rs17413194, rs17856153, rs198363, rs3189984, rs57081035
A > G
SNP
*152R
No VIP available No Clinical Annotations available VA
rs6025 NC_000001.10:g.169519049T=, NC_000001.10:g.169519049T>C, NC_000001.11:g.169549811C=, NC_000001.11:g.169549811C>T, NG_011806.1:g.41721G=, NG_011806.1:g.41721G>A, NM_000130.4:c.1601G=, NM_000130.4:c.1601G>A, NP_000121.2:p.Arg534=, NP_000121.2:p.Arg534Gln, rs1801711, rs60031897
T > C
SNP
R534Q
No VIP available No Clinical Annotations available VA
rs662 NC_000007.13:g.94937446T>C, NC_000007.14:g.95308134T>C, NG_008779.1:g.21439A>G, NM_000446.5:c.575A>G, NP_000437.3:p.Gln192Arg, rs11567868, rs13306697, rs17773773, rs386603940, rs60480675
T > C
SNP
Q192R
No VIP available CA VA
rs669 NC_000012.11:g.9232268T>C, NC_000012.12:g.9079672T>C, NG_011717.1:g.41291A>G, NM_000014.4:c.2998A>G, NP_000005.2:p.Ile1000Val, XM_006719056.2:c.2998A>G, XP_006719119.1:p.Ile1000Val, rs10432, rs1049149, rs10743597, rs116906878, rs17354152, rs17853961, rs2228223, rs3168556, rs52792261, rs57589145
T > C
SNP
I1000V
No VIP available No Clinical Annotations available VA
rs6798347 NC_000003.11:g.151106158G>A, NC_000003.12:g.151388370G>A, NG_016019.1:g.1387C>T, NG_021244.1:g.306483G>A, NM_053002.5:c.5346+198G>A, XM_005247096.1:c.5451+198G>A, XM_006713487.2:c.5451+198G>A, XM_011512386.1:c.5451+198G>A, XM_011512387.1:c.5448+198G>A, XM_011512388.1:c.5451+198G>A, XM_011512389.1:c.5346+198G>A, XM_011512390.1:c.5346+198G>A, XM_011512391.1:c.5181+198G>A, XM_011512392.1:c.4995+198G>A, XM_011512393.1:c.5451+198G>A, XM_011512394.1:c.5451+198G>A, XM_011512395.1:c.5451+198G>A, XM_011512396.1:c.3876+198G>A, XM_011512397.1:c.3318+198G>A, XM_011512398.1:c.3246+198G>A, XM_011512400.1:c.2268+198G>A, rs13070478, rs59029418
G > A
SNP
No VIP available No Clinical Annotations available VA
rs6798637
G > C
G > T
SNP
No VIP available No Clinical Annotations available VA
rs699 NC_000001.10:g.230845794A>G, NC_000001.11:g.230710048A>G, NG_008836.1:g.9543T>C, NM_000029.3:c.803T>C, NP_000020.1:p.Met268Thr, rs17856353, rs3182295, rs386606420, rs4714, rs61617185
A > G
SNP
M268T
No VIP available No Clinical Annotations available VA
rs762551 NC_000015.10:g.74749576C>A, NC_000015.9:g.75041917C>A, NG_008431.1:g.32035C>A, NM_000761.3:c.-9-154C>A, NM_000761.4:c.-9-154C>A, rs17861151, rs57172993
C > A
SNP
No VIP available No Clinical Annotations available VA
rs7634096
C > T
SNP
No VIP available No Clinical Annotations available VA
rs776746 NC_000007.13:g.99270539C>T, NC_000007.14:g.99672916T>C, NG_007938.1:g.12083G=, NG_007938.1:g.12083G>A, NM_000777.4:c.219-237A>G, NM_000777.4:c.219-237G>A, NM_001190484.2:c.219-237A>G, NM_001190484.2:c.219-237G>A, NM_001291829.1:c.-253-1A>G, NM_001291829.1:c.-253-1G>A, NM_001291830.1:c.189-237A>G, NM_001291830.1:c.189-237G>A, NR_033807.2:n.717-1A>G, NR_033807.2:n.717-1G>A, NR_033808.1:n.689-1G>A, NR_033809.1:n.581-237G>A, NR_033810.1:n.689-1G>A, NR_033811.1:n.321-1G>A, NR_033812.1:n.321-1G>A, XM_005250169.1:c.189-237G>A, XM_005250170.1:c.-357-1G>A, XM_005250171.1:c.-253-1G>A, XM_005250172.1:c.-254G>A, XM_005250173.1:c.-331-237G>A, XM_005250198.1:c.806-4288C>T, XM_006715859.2:c.219-237A>G, XM_011515843.1:c.-254A>G, XM_011515844.1:c.-229-237A>G, XM_011515845.1:c.-463-1A>G, XM_011515846.1:c.-331-237A>G, XM_011515847.1:c.-571-1A>G, XR_927383.1:n.344-237A>G, XR_927402.1:n.1466+48736T>C, rs10361242, rs11266830, rs386613022, rs58244770
C > T
SNP
No VIP available CA No Variant Annotations available
rs7900194 NC_000010.10:g.96702066G>A, NC_000010.11:g.94942309G>A, NG_008385.1:g.8652G>A, NM_000771.3:c.449G>A, NP_000762.2:p.Arg150His, XM_005269575.1:c.449G>A, XP_005269632.1:p.Arg150His, rs57530584
G > A
SNP
R150H
No VIP available CA VA
rs8192950
T > G
SNP
No VIP available CA No Variant Annotations available
rs9332131 NC_000010.10:g.96709039delA, NC_000010.11:g.94949282delA, NG_008385.1:g.15625delA, NM_000771.3:c.817delA, NP_000762.2:p.Lys273Argfs, XM_005269575.1:c.817delA, XP_005269632.1:p.Lys273Argfs
A > -
indel
K273R
No VIP available No Clinical Annotations available VA
rs9859538
G > A
SNP
No VIP available No Clinical Annotations available VA
rs9923231 NC_000016.10:g.31096368C=, NC_000016.10:g.31096368C>T, NC_000016.9:g.31107689C=, NC_000016.9:g.31107689C>T, NG_011564.1:g.3588G=, NG_011564.1:g.3588G>A, NM_001311311.1:c.-1639G=, NM_001311311.1:c.-1639G>A, NM_024006.5:c.-1639G=, NM_024006.5:c.-1639G>A, NM_206824.2:c.-1639G=, NM_206824.2:c.-1639G>A, XM_005255568.1:c.-1639G=, XM_005255568.1:c.-1639G>A, XM_011545943.1:c.-1639G=, XM_011545943.1:c.-1639G>A, XM_011545944.1:c.-1252G=, XM_011545944.1:c.-1252G>A, XM_011545945.1:c.-1252G=, XM_011545945.1:c.-1252G>A, XR_243303.1:n.-990G=, XR_243303.1:n.-990G>A, XR_950848.1:n.-31G=, XR_950848.1:n.-31G>A, rs117572127, rs17878363, rs60511154
C > A
C > G
C > T
SNP
No VIP available CA VA
rs9934438 NC_000016.10:g.31093557G>A, NC_000016.9:g.31104878G>A, NG_011564.1:g.6399C>T, NM_001311311.1:c.174-136C>T, NM_024006.5:c.174-136C>T, NM_206824.2:c.173+1000C>T, XM_005255568.1:c.174-136C>T, XM_011545943.1:c.174-136C>T, XM_011545944.1:c.174-136C>T, XM_011545945.1:c.173+1000C>T, XR_243303.1:n.823-236C>T, XR_950848.1:n.962-136C>T, rs17641219
G > A
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Alternate Names: 
Synonym
Accident, Acute Cerebrovascular; Accident, Brain Vascular; Accident, Cerebrovascular; Accidents, Acute Cerebrovascular; Accidents, Brain Vascular; Accidents, Cerebrovascular; Acute Cerebrovascular Accident; Acute Cerebrovascular Accidents; Acute Stroke; Acute Strokes; Apoplexy; Apoplexy, Cerebrovascular; Brain Vascular Accident; Brain Vascular Accidents; CVA (Cerebrovascular Accident); CVA - Cerebrovascular accident; CVAs (Cerebrovascular Accident); Cerebral Stroke; Cerebral Strokes; Cerebrovascular Accident; Cerebrovascular Accident, Acute; Cerebrovascular Accidents; Cerebrovascular Accidents, Acute; Cerebrovascular Apoplexy; Cerebrovascular Stroke; Cerebrovascular Strokes; Cerebrovascular accident; Infarction, Posterior Cerebral Artery; Stroke; Stroke, Acute; Stroke, Cerebral; Stroke, Cerebrovascular; Strokes; Strokes, Acute; Strokes, Cerebral; Strokes, Cerebrovascular; Vascular Accident, Brain; Vascular Accidents, Brain
PharmGKB Accession Id: PA447054
External Vocabularies

Curated Information ?

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
May Prevent
Contraindicated With

Curated Information ?

EvidenceDisease
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Atrial Fibrillation

Publications related to Stroke: 143

No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
The Impact of CYP2C19 Loss-of-Function Polymorphisms, Clinical, and Demographic Variables on Platelet Response to Clopidogrel Evaluated Using Impedance Aggregometry. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2017. Mărginean Alina, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis. Circulation. 2017. Pan Yuesong, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population. BMC research notes. 2016. Kudzi William, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
VKORC1 and CYP2C9 polymorphisms related to adverse events in case-control cohort of anticoagulated patients. Medicine. 2016. Misasi Silvia, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Impact of genetic polymorphisms related to clopidogrel or acetylsalicylic acid pharmacology on clinical outcome in Chinese patients with symptomatic extracranial or intracranial stenosis. European journal of clinical pharmacology. 2016. Zhao Zhigang, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Direct oral anticoagulants for stroke prevention in patients with atrial fibrillation: meta-analysis by geographic region with a focus on european patients. British journal of clinical pharmacology. 2016. Gómez-Outes Antonio A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Interaction of CYP2C19, P2Y12, and GPIIIa Variants Associates With Efficacy of Clopidogrel and Adverse Events on Patients With Ischemic Stroke. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2016. Yi Xingyang, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Development and Comparison of Warfarin Dosing Algorithms in Stroke Patients. Yonsei medical journal. 2016. Cho Sun Mi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Association of Cytochrome P450 Genetic Variants with Clopidogrel Resistance and Outcomes in Acute Ischemic Stroke. Journal of atherosclerosis and thrombosis. 2016. Yi Xingyang, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves. Cardiovascular therapeutics. 2015. An Sook Hee, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. PloS one. 2016. Duconge Jorge, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Management of Central Poststroke Pain: Systematic Review of Randomized Controlled Trials. Stroke; a journal of cerebral circulation. 2015. Mulla Sohail M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. European journal of clinical pharmacology. 2015. Chung Jee-Eun, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Genetic and platelet function testing of antiplatelet therapy for percutaneous coronary intervention: the ARCTIC-GENE study. European journal of clinical pharmacology. 2015. Collet Jean-Philippe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Clinical Application of Genotype-guided Dosing of Warfarin in Patients with Acute Stroke. Archives of medical research. 2015. Šupe Svjetlana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis. Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban. 2015. Niu Xuan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of clinical factors and gene polymorphism of CYP2C19*2, *17 and CYP4F2*3 on early stent thrombosis. Pharmacogenomics. 2015. Kupstyte Nora, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. Stroke; a journal of cerebral circulation. 2015. Leonard Charles E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Circulating atrial natriuretic peptide genetic association study identifies a novel gene cluster associated with stroke in whites. Circulation. Cardiovascular genetics. 2015. Pereira Naveen L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
CYP2C19 genotype and early ischemic lesion recurrence in stroke patients treated with clopidogrel. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association. 2015. Jeong Tae-Dong, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Effects of CYP2C19 and P2Y12 Gene Polymorphisms on Clinical Results of Patients Using Clopidogrel after Acute Ischemic Cerebrovascular Disease. Balkan journal of medical genetics : BJMG. 2014. Sen H M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The foundation of precision medicine: integration of electronic health records with genomics through basic, clinical, and translational research. Frontiers in genetics. 2015. Ritchie Marylyn D, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
CYP2C19 Metabolizer Status and Clopidogrel Efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) Study. Journal of the American Heart Association. 2015. McDonough Caitrin W, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Universal versus genotype-guided use of direct oral anticoagulants in atrial fibrillation patients: a decision analysis. Pharmacogenomics. 2015. You Joyce H S. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Pharmacogenetic effects of 'candidate gene complexes' on stroke in the GenHAT study. Pharmacogenetics and genomics. 2014. Sørensen Izel F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Impact of GATA4 variants on stable warfarin doses in patients with prosthetic heart valves. The pharmacogenomics journal. 2014. Jeong E, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genome-Wide Meta-Analysis of Homocysteine and Methionine Metabolism Identifies Five One Carbon Metabolism Loci and a Novel Association of ALDH1L1 with Ischemic Stroke. PLoS genetics. 2014. Williams Stephen R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. European journal of clinical pharmacology. 2014. Krishna Kumar Dhakchinamoorthi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Verification of pharmacogenetics-based warfarin dosing algorithms in han-chinese patients undertaking mechanic heart valve replacement. PloS one. 2014. Zhao Li, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
PON1 Q192R genotype influences clopidogrel responsiveness by relative platelet inhibition instead of on-treatment platelet reactivity. Thrombosis research. 2013. Li Xiaoqi, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Stroke Genetics Network (SiGN) Study: Design and Rationale for a Genome-Wide Association Study of Ischemic Stroke Subtypes. Stroke; a journal of cerebral circulation. 2013. Meschia James F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacogenomics of anti-platelet and anti-coagulation therapy. Current cardiology reports. 2013. Fisch Adam S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Challenges in pharmacogenetics. European journal of clinical pharmacology. 2013. Cascorbi Ingolf, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Intestinal microbiota metabolism of l-carnitine, a nutrient in red meat, promotes atherosclerosis. Nature medicine. 2013. Koeth Robert A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and clinical determinants influencing warfarin dosing in children with heart disease. Pediatric cardiology. 2013. Nguyen Nguyenvu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genes involved in hemorrhagic transformations that follow recombinant t-PA treatment in stroke patients. Pharmacogenomics. 2013. Fernandez-Cadenas Israel, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The influence of VKORC1 and CYP2C9 gene sequence variants on the stability of maintenance phase warfarin treatment. Thrombosis research. 2013. Skov Jane, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Loci influencing blood pressure identified using a cardiovascular gene-centric array. Human molecular genetics. 2013. Ganesh Santhi K, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects. Pharmacogenetics and genomics. 2013. Cavallari Larisa H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Paraoxonase-1 Q192R polymorphism is not associated with clopidogrel response in Chinese stroke patients. Die Pharmazie. 2012. Yang Jie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Levels of cholesterol in small LDL particles predict atherosclerosis progression and incident CHD in the HDL-Atherosclerosis Treatment Study (HATS). PloS one. 2013. Williams Paul T, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin anticoagulant therapy: a southern Italy pharmacogenetics-based dosing model. PloS one. 2013. Mazzaccara Cristina, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A predictive clinical-genetic model of tissue plasminogen activator response in acute ischemic stroke. Annals of neurology. 2012. del Río-Espínola Alberto, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Bedside monitoring to adjust antiplatelet therapy for coronary stenting. The New England journal of medicine. 2012. Collet Jean-Philippe, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Race-Specific Impact of Atrial Fibrillation Risk Factors in Blacks and Whites in the Southern Community Cohort Study. The American journal of cardiology. 2012. Lipworth Loren, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. Pharmacogenomics. 2012. Pavani Addepalli, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. Therapeutic drug monitoring. 2012. Lee Kyung-Eun, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Thrombosis and haemostasis. 2012. Wei Meng, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clinical pharmacology and therapeutics. 2012. Liu Y, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms are associated with variations in warfarin maintenance dose in Han Chinese patients with venous thromboembolism. Pharmacogenomics. 2012. Zhang Wei, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Platelets. 2012. Marcucci Rossella, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cholesteryl Ester Transfer Protein (CETP) polymorphisms affect mRNA splicing, HDL levels, and sex-dependent cardiovascular risk. PloS one. 2012. Papp Audrey C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Clinical therapeutics. 2011. Cho Hyun-Jung, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Paraoxonase 1 (PON1) Gene Variants Are Not Associated With Clopidogrel Response. Clinical pharmacology and therapeutics. 2011. Lewis J P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of the VKORC1 genotype on warfarin dose requirements in Japanese pediatric patients. Drug metabolism and pharmacokinetics. 2011. Kato Yuya, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Carrying one or two reduced-function CYP2C19 alleles is associated with an increased risk of major adverse cardiovascular events in people undergoing percutaneous coronary intervention and treated with clopidogrel. Evidence-based medicine. 2011. Ramirez Andrea H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Liver X receptor alpha gene polymorphisms and variable cardiovascular outcomes in patients treated with antihypertensive therapy: results from the INVEST-GENES study. Pharmacogenetics and genomics. 2011. Price Elvin Tyrone, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics. 2011. Mitchell Cathrine, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vanin-1 T26I polymorphism, hypertension and cardiovascular events in two large urban-based prospective studies in Swedes. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2011. Fava C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. Journal of human genetics. 2011. Choi Jung Ran, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation. International journal of clinical pharmacology and therapeutics. 2011. Yang J, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin dosing algorithm using clinical, demographic and pharmacogenetic data from Chinese patients. Journal of thrombosis and thrombolysis. 2011. You Joyce H S, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and nongenetic factors associated with warfarin doserequirements in Egyptian patients. Pharmacogenetics and genomics. 2011. Shahin Mohamed Hossam A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The cytochrome 2C19*2 and *3 alleles attenuate response to clopidogrel similarly in East Asian patients undergoing elective percutaneous coronary intervention. Thrombosis research. 2011. Hwang Seok-Jae, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The effect of CYP2C9, VKORC1 genotypes and old age on warfarin pharmacologic sensitivity in korean patients with thromboembolic disease. Annals of clinical and laboratory science. 2011. Moon Hee-Won, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variation in the beta2 subunit of the voltage-gated calcium channel and pharmacogenetic association with adverse cardiovascular outcomes in the INternational VErapamil SR-Trandolapril STudy GENEtic Substudy (INVEST-GENES). Circulation. Cardiovascular genetics. 2010. Niu Yuxin, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. Journal of biomedicine & biotechnology. 2011. Kringen Marianne K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The C3435T polymorphism in ABCB1 influences atorvastatin efficacy and muscle symptoms in a high-risk vascular cohort. Journal of clinical lipidology. 2011. Hoenig Michel R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
PharmGKB summary: very important pharmacogene information for PTGS2. Pharmacogenetics and genomics. 2010. Thorn Caroline F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive-treated patients. Pharmacogenetics and genomics. 2010. Lobmeyer Maximilian T, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Systematic review of pharmacoeconomic studies of pharmacogenomic tests. Pharmacogenomics. 2010. Beaulieu Mathieu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA : the journal of the American Medical Association. 2010. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial. Lancet. 2010. Wallentin Lars, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic variants in ABCB1 and CYP2C19 and cardiovascular outcomes after treatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial: a pharmacogenetic analysis. Lancet. 2010. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CD40-1C>T polymorphism (rs1883832) is associated with brain vessel reocclusion after fibrinolysis in ischemic stroke. Pharmacogenomics. 2010. del Río-Espínola Alberto, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. Journal of thrombosis and haemostasis : JTH. 2010. Lubitz S A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
COC use, ACE/AGT gene polymorphisms, and risk of stroke. Pharmacogenetics and genomics. 2010. Li Ying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Vitamin E reduces cardiovascular disease in individuals with diabetes mellitus and the haptoglobin 2-2 genotype. Pharmacogenomics. 2010. Blum Shany, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Can we predict daily adherence to warfarin?: Results from the International Normalized Ratio Adherence and Genetics (IN-RANGE) Study. Chest. 2010. Platt Alec B, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic and clinical predictors of warfarin dose requirements in African Americans. Clinical pharmacology and therapeutics. 2010. Cavallari L H, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pharmacodynamics and pharmacokinetics of AM103, a novel inhibitor of 5-lipoxygenase-activating protein (FLAP). Clinical pharmacology and therapeutics. 2010. Bain G, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Association of common variants of CYP4A11 and CYP4F2 with stroke in the Han Chinese population. Pharmacogenetics and genomics. 2010. Ding Hu, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 2C19(*)2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis. The pharmacogenomics journal. 2010. Sofi F, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
HMGCR gene polymorphism is associated with stroke risk in the EPIC-Norfolk study. European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology. 2010. Freitas Renata N, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes. Pharmacogenetics and genomics. 2010. Fava Cristiano, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common polymorphisms in CYP2C9, subclinical atherosclerosis and risk of ischemic vascular disease in 52,000 individuals. The pharmacogenomics journal. 2009. Kaur-Knudsen D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Dabigatran versus warfarin in patients with atrial fibrillation. The New England journal of medicine. 2009. Connolly Stuart J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
CACNA1C gene polymorphisms, cardiovascular disease outcomes, and treatment response. Circulation. Cardiovascular genetics. 2009. Beitelshees Amber L, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Exploring warfarin pharmacogenomics with the extreme-discordant-phenotype methodology: impact of FVII polymorphisms on stable anticoagulation with warfarin. European journal of clinical pharmacology. 2009. Fuchshuber-Moraes Mateus, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing. Pharmacogenomics. 2009. Scott Stuart A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mutations in smooth muscle alpha-actin (ACTA2) cause coronary artery disease, stroke, and Moyamoya disease, along with thoracic aortic disease. American journal of human genetics. 2009. Guo Dong-Chuan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome p-450 polymorphisms and response to clopidogrel. The New England journal of medicine. 2009. Mega Jessica L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic determinants of response to clopidogrel and cardiovascular events. The New England journal of medicine. 2009. Simon Tabassome, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. The New England journal of medicine. 2009. Wallentin Lars, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genomewide association studies of stroke. The New England journal of medicine. 2009. Ikram M Arfan, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Validation of VKORC1 and CYP2C9 genotypes on interindividual warfarin maintenance dose: a prospective study in Chinese patients. Pharmacogenetics and genomics. 2009. Huang Sheng-Wen, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement. Pharmacogenetics and genomics. 2009. Kim Ho-Sook, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood cells, molecules & diseases. 2009. Limdi N A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Interaction between polymorphisms in the renin-angiotensin-system and angiotensin-converting enzyme inhibitor or beta-blocker use and the risk of myocardial infarction and stroke. The pharmacogenomics journal. 2008. Schelleman H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
VKORC1 polymorphisms, haplotypes and haplotype groups on warfarin dose among African-Americans and European-Americans. Pharmacogenomics. 2008. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common genetic variation in six lipid-related and statin-related genes, statin use and risk of incident nonfatal myocardial infarction and stroke. Pharmacogenetics and genomics. 2008. Hindorff Lucia A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Common variation in cytochrome P450 epoxygenase genes and the risk of incident nonfatal myocardial infarction and ischemic stroke. Pharmacogenetics and genomics. 2008. Marciante Kristin D, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Combination of phenotype assessments and CYP2C9-VKORC1 polymorphisms in the determination of warfarin dose requirements in heavily medicated patients. Clinical pharmacology and therapeutics. 2008. Michaud V, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. JAMA : the journal of the American Medical Association. 2008. Lynch Amy I, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic determinants of response to warfarin during initial anticoagulation. The New England journal of medicine. 2008. Schwarz Ute I, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Increased risk of incident stroke associated with the cyclooxygenase 2 (COX-2) G-765C polymorphism in African-Americans: the Atherosclerosis Risk in Communities Study. Atherosclerosis. 2008. Kohsaka Shun, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin. Clinical pharmacology and therapeutics. 2008. Limdi N A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Cyclooxygenase polymorphisms and risk of cardiovascular events: the Atherosclerosis Risk in Communities (ARIC) study. Clinical pharmacology and therapeutics. 2008. Lee C R, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation. 2007. Anderson Jeffrey L, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Long-term follow-up of the West of Scotland Coronary Prevention Study. The New England journal of medicine. 2007. Ford Ian, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood. 2007. Millican Eric A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A new genetic disorder in mitochondrial fatty acid beta-oxidation: ACAD9 deficiency. American journal of human genetics. 2007. He M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Ethnic differences in the VKORC1 gene polymorphism and an association with warfarin dosage requirements in cardiovascular surgery patients. Pharmacogenomics. 2007. Nakai Kenji, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Warfarin response and vitamin K epoxide reductase complex 1 in African Americans and Caucasians. Clinical pharmacology and therapeutics. 2007. Schelleman H, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Influence of CYP2C9 Genotype on warfarin dose among African American and European Americans. Personalized medicine. 2007. Limdi Na, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Effects of torcetrapib in patients at high risk for coronary events. The New England journal of medicine. 2007. Barter Philip J, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. The New England journal of medicine. 2007. Warfarin Antiplatelet Vascular Evaluation Trial Investigators, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Prasugrel versus clopidogrel in patients with acute coronary syndromes. The New England journal of medicine. 2007. Wiviott Stephen D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Rosuvastatin in older patients with systolic heart failure. The New England journal of medicine. 2007. Kjekshus John, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Angiotensinogen M235T polymorphism and the risk of myocardial infarction and stroke among hypertensive patients on ACE-inhibitors or beta-blockers. European journal of human genetics : EJHG. 2007. Schelleman Hedi, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Factors affecting the interindividual variability of warfarin dose requirement in adult Korean patients. Pharmacogenomics. 2007. Cho Hyun-Jung, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study. Journal of thrombosis and thrombolysis. 2006. Carlquist John F, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Multiple gene polymorphisms and warfarin sensitivity. European journal of clinical pharmacology. 2006. Shikata Eriko, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation. Journal of medical genetics. 2006. Li T, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Oral contraceptive use, thrombophilia and their interaction in young women with ischemic stroke. Haematologica. 2006. Martinelli Ida, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thrombosis and haemostasis. 2006. Herman Darja, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin pharmacology, clinical management, and evaluation of hemorrhagic risk for the elderly. Clinics in geriatric medicine. 2006. Jacobs Laurie G. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients. Journal of human genetics. 2006. Mushiroda Taisei, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
1173C>T polymorphism in VKORC1 modulates the required warfarin dose. Pediatric cardiology. 2006. Kosaki K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Evaluation of the paraoxonases as candidate genes for stroke: Gln192Arg polymorphism in the paraoxonase 1 gene is associated with increased risk of stroke. Stroke; a journal of cerebral circulation. 2005. Ranade Koustubh, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
VKORC1 haplotypes and their impact on the inter-individual and inter-ethnical variability of oral anticoagulation. Thrombosis and haemostasis. 2005. Geisen Christof, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic polymorphisms and the risk of stroke after cardiac surgery. Stroke; a journal of cerebral circulation. 2005. Grocott Hilary P, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenetics and genomics. 2005. Tai Guoying, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Prothrombotic conditions, oral contraceptives, and the risk of ischemic stroke. Journal of thrombosis and haemostasis : JTH. 2005. Slooter A J C, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005. D'Andrea Giovanna, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Common VKORC1 and GGCX polymorphisms associated with warfarin dose. The pharmacogenomics journal. 2005. Wadelius M, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Venous thromboembolic disease in users of low-estrogen combined estrogen-progestin oral contraceptives. Contraception. 2004. Sidney Stephen, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
A polymorphism in the cyclooxygenase 2 gene as an inherited protective factor against myocardial infarction and stroke. JAMA : the journal of the American Medical Association. 2004. Cipollone Francesco, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
CYP2C9 genetic polymorphisms and warfarin. Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis. 2004. Redman Andrea R, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available VA No VIP available No VIP available
Angiotensinogen Met235Thr polymorphism, angiotensin-converting enzyme inhibitor therapy, and the risk of nonfatal stroke or myocardial infarction in hypertensive patients. American journal of hypertension. 2003. Bis Joshua C, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension. 2003. Harrap Stephen B, et al. PubMed
No Dosing Guideline available No Drug Label available CA No Variant Annotation available No VIP available No VIP available
Venous thromboembolism in young women; role of thrombophilic mutations and oral contraceptive use. European heart journal. 2002. Legnani C, et al. PubMed